Eisai (4523.T)

Executive Summary

Eisai Co., Ltd. is a Japanese pharmaceutical company with a strong legacy in neurology and oncology, underpinned by its 'human health care' philosophy. The company's commercial portfolio includes blockbuster drugs like Donepezil (Aricept) for Alzheimer's and Lemborexant (Dayvigo) for insomnia, providing a stable revenue base. Eisai's strategic focus on Alzheimer's disease is highlighted by its co-development of Leqembi (lecanemab) with Biogen, which received FDA approval in 2023 for early Alzheimer's. In oncology, Eisai markets Lenvima (lenvatinib) and Halaven (eribulin), addressing significant unmet needs. The company also demonstrates a commitment to global health through initiatives targeting neglected tropical diseases. Looking ahead, Eisai's near-term growth is tied to the continued commercial expansion of Leqembi, pending full FDA approval and reimbursement decisions. The company is also advancing Lemborexant for delayed sleep phase syndrome (DSPS), with a Phase 3 trial ongoing (NCT06874855). Additionally, Eisai's pipeline includes potential label expansions for Lenvima in combination therapies and early-stage candidates in neurology. However, competition in Alzheimer's and pricing pressures pose risks. Overall, Eisai's diversified portfolio and strong R&D focus position it for sustained growth, though near-term catalysts are largely dependent on regulatory and market adoption.

Upcoming Catalysts (preview)

• Q2 2026Leqembi (lecanemab) full FDA approval and launch ramp for early Alzheimer's disease80% success
• Q2 2027Lemborexant Phase 3 data readout for delayed sleep phase syndrome70% success
• Q4 2026Lenvima combination therapy label expansion results in oncology60% success